Physician profile
Bonnie Wise
NPI 1871559120
$2,258.37
in general payments reported to CMS, 2019-2025
24 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $100 · 2021: $44.03 · 2022: $935 · 2023: $465 · 2024: $241 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $780.13 | 2020-2025 | Lo Loestrin Fe, Liletta |
| Hologic Sales and Service, LLC | $166.22 | 2019-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Aptima |
| Mayne Pharma Commercial LLC | $153.99 | 2022-2024 | |
| Avion Pharmaceuticals | $133.16 | 2021-2023 | Balcoltra |
| Organon LLC | $110.52 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $92.64 | 2019-2022 | |
| Myovant Sciences INC. | $85.24 | 2022 | |
| Merck Sharp & Dohme LLC | $85.13 | 2019-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Coopersurgical, INC. | $82.22 | 2019-2025 | Paragard T 380a |
| Channel Medsystems, INC. | $66.34 | 2022-2023 | |
| Allergan, INC. | $61.64 | 2019-2020 | |
| Novo Nordisk INC | $61.63 | 2023-2024 | Wegovy |
| Millicent US INC | $61.58 | 2025 | Intrarosa |
| Astellas Pharma US INC | $59.00 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $44.84 | 2020-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $37.17 | 2019 | |
| Becton, Dickinson and Company | $35.14 | 2023 | Bd Max System, Bd Max Instrument |
| Sumitomo Pharma America, INC. | $29.31 | 2023 | Myfembree |
| Boston Scientific Corporation | $28.56 | 2019 | |
| Pfizer INC. | $23.01 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.51 | 2019 | |
| Duchesnay USA Incorporated | $15.33 | 2019 | |
| Lupin INC. | $14.35 | 2019 | |
| Scynexis, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.